Loading data for GRFS — first visit, this takes a few seconds.
Grifols, S.A. (GRFS)
NasdaqGS: GRFS
· 即時價格 · USD
7.80
-0.08 (-1.02%)
收盤價： Sep 04, 2026, 8:00 PM
股價、關鍵數字和最新消息，都在這一頁。
Grifols, S.A.（GRFS）股價、分析與資料
無可用資料
| 買價 | 6.72 |
| 市值 | 5.31B |
| 營收 (ttm) | 7.42B |
| 淨利（ttm） | 452M |
| 1.19 | |
| 0.77 | |
| 10.13 | |
| 5.41 | |
| P/B (ttm) | 1.65 |
| P/S (ttm) | 0.72 |
| 財報日期 | Feb 25, 2027 |
| 賣價 | 8.94 |
| 成交量 | 157,911 |
| 20 日平均成交量 | 620,765 |
| 開盤價 | 7.81 |
| 前收盤價 | 7.88 |
| 當日區間 | 7.78 - 7.84 |
| 52 週範圍 | 6.96 - 10.23 |
| 分析師 | n/a |
| 目標價 | n/a |
| 股利 | $0.28 (3.61%) |
| 除息日 | Jul 2, 2026 |
關於 GRFS
Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. It operates through four segments: Biopharma, Diagnostic, Bio Supplies, and Others. The company offers various hemoderivatives from human plasma for immunology, infectious diseases, hepatology, intensive care, pulmonology, hematology, and neurol...
完整的公司簡介財報驚奇
Grifols, S.A. 已於 Jul 28, 2025 公布季度財報：
- 營收為 $1.87B 低於預期 $0, 年增 4.93% 成長.
- 每股盈餘為 0.22 低於預期 -0.06, 年增 -24.14% 下滑.
第 1 頁，共 2 頁